

SUBSTITUTE FORM PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

Attorney Docket No.	50150/055003
Serial No.	10/652,799
Applicant	Barry Eisenstein et al.
Filing Date	August 29, 2003
Group	1651
IDS Filed	January 11, 2005
Customer No.	21559

## U.S. PATENTS

Examiner's Initials	Patent Number or Patent Application No.	Issue Date or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
bf	6,506,407	1/14/03	Wantanabe et al.			
	6,488,962	12/3/02	Berner et al.			
	6,340,475	1/22/02	Shell et al.			
	6,319,518	11/20/01	Lee et al.			
	6,316,433	11/13/01	Rose et al.			
	6,270,755	8/07/01	Kurtz et al.			
	5,972,389	10/26/99	Shell et al.			
	5,968,554	10/19/99	Belman et al.			
	5,962,024	10/5/99	Marvola et al.			
	5,849,327	12/15/98	Berliner et al.			
	5,811,388	9/22/98	Friend et al.			
	5,773,000	06/30/98	Bostwick et al.			
	5,582,837	12/10/96	Shell			
	5,547,683	8/20/96	Yano et al.			
	5,525,634	6/11/96	Sintov et al.			
	5,266,315	11/30/93	Taguchi et al.			
	5,007,790	4/16/91	Shell			
	4,983,602	01/08/91	Yamane et al.			
bf	2004/0034021	02/19/04	Michaelis et al.			

EXAMINER

Blessing Tubana

DATE CONSIDERED

4-01-05

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to application.



Sheet 2 of 3

SUBSTITUTE PATENT PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50150/055003
		Serial No.	10/652,799
		Applicant	Barry Eisenstein et al.
		Filing Date	August 29, 2003
		Group	1651
		IDS Filed	January 11, 2005
(37 C.F.R. § 1.98(b))		Customer No.	21559

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

BF	Alfa et al., "Survey of Incidence of <i>Clostridium difficile</i> Infection in Canadian Hospitals and Diagnostic Approaches," <i>J. Clin. Microbiol.</i> 36:2076-2080 (1998).
	Anton et al., "Rifalazil Prevents and Treats <i>Clostridium difficile</i> -Associated Infection in Hamsters," Abstract ID No. 102471, Publishing ID No. T1741, presented at the American Gastroenterological Association Meeting.
	Anton et al., "Rifalazil Prevents and Treats <i>Clostridium Difficile</i> -Associated Infection in Hamsters," Abstract, presented at the Digestive Disease Weekly Annual Meeting, May 2003.
	Bartlett et al., "Clindamycin-Associated Colitis Due to a Toxin-Producing Species of <i>Clostridium</i> in Hamsters," <i>J. Infect. Dis.</i> 136:701-705 (1977).
	Bartlett et al., "Treatment of Antibiotic-Associated Pseudomembranous Colitis," <i>Rev. Infect. Dis.</i> 6:S235-S241 (1984).
	Boon et al., "Studies with Temocillin in the Hamster Model of Antibiotic-Associated Colitis," <i>Drugs</i> 29 (Suppl. 5) 57-63 (1985).
	Buggy et al., "Therapy of Relapsing <i>Clostridium difficile</i> -Associated Diarrhea and Colitis with the Combination of Vancomycin and Rifampin," <i>J. Clin. Gastroenterol.</i> 9:155-159 (1987).
	Declaration of Barry Eisenstein
	Fekety, R., "Guidelines for the Diagnosis and Management of <i>Clostridium difficile</i> -Associated Diarrhea and Colitis," Practice Parameters Committee, <i>Am. J. Gastroenterol.</i> 92:739-750 (1997).
	Fujii et al., "In Vitro and In Vivo Antibacterial Activities of KRM-1648 and KRM-1657, New Rifamycin Derivatives," <i>Antimicrob. Agents Chemother.</i> 38:1118-1122 (1994).
	Gorbach et al., "Successful Treatment of Relapsing <i>Clostridium difficile</i> Colitis with <i>Lactobacillus</i> GG," <i>Lancet</i> 2:1519 (1987).
	Hirata et al., "In Vitro and In Vivo Activities of the Benzoxazinorifamycin KRM-1648 against <i>Mycobacterium tuberculosis</i> ," <i>Antimicrob. Agents Chemother.</i> 39:2295-2303 (1995).
	Kelly et al., " <i>Clostridium difficile</i> Colitis," <i>N. Engl. J. Med.</i> 330:257-262 (1994).
	Klemens et al., "Activity of KRM-1648 in Combination with Isoniazid Against <i>Mycobacterium tuberculosis</i> in a Murine Model," <i>Antimicrob. Agents Chemother.</i> 40:298-301 (1996).
	Kunimoto et al., "Recurrent <i>Clostridium difficile</i> -Associated Colitis Responding to Cholestyramine," <i>Digestion</i> 33:225-228 (1986).
	Kurtz et al., "GT160-246, a Toxin Binding Polymer for Treatment of <i>Clostridium difficile</i> Colitis," <i>Antimicrob. Agents Chemother.</i> 45:2340-2347 (2001).
	Kyne et al., " <i>Clostridium difficile</i> ," <i>Gastroenterol. Clinics</i> 30:1-25 (2001).
BF	Kyne et al., "Recurrent <i>Clostridium difficile</i> Diarrhoea," <i>Gut</i> 49:152-153 (2001).

EXAMINER

Blessing Fubara

DATE CONSIDERED

4-01-05

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



Sheet 3 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50150/055003	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Serial No.	10/652,799	
				Applicant	Barry Eisenstein et al.	
				Filing Date	August 29, 2003	
				Group	1651	
				IDS Filed	January 11, 2005	
(37 C.F.R. § 1.98(b))				Customer No.	21559	
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
BF		Lai et al., <i>Clostridium difficile</i> -Associated Diarrhea: Epidemiology, Risk Factors, and Infection Control," <i>Infect. Control Hosp. Epidemiol.</i> 18:628-632 (1997).				
		Lenaerts et al., "Evaluation of Rifalazil in a Combination Treatment Regimen as an Alternative to Isoniazid-Rifampin Therapy in a Mouse Tuberculosis Model," <i>Antimicrob. Agents Chemother.</i> 44:3167-3168 (2000).				
		Leung et al., "Treatment with Intravenously Administered Gamma Globulin of Chronic Relapsing Colitis Induced by <i>Clostridium difficile</i> Toxin," <i>J. Pediatr.</i> 118:633-637 (1991).				
		McFarland et al., "Breaking the Cycle: Treatment Strategies for 163 Cases of Recurrent <i>Clostridium difficile</i> Disease," <i>Am. J. Gastroenterol.</i> 97:1769-1775 (2002).				
		McFarland et al., "A Randomized Placebo-Controlled Trial of <i>Saccharomyces boulardii</i> in Combination with Standard Antibiotics for <i>Clostridium difficile</i> Disease," <i>JAMA</i> 271:1913-1918 (1994).				
		McVay et al., "In Vitro and In Vivo Activities of Nitazoxanide Against <i>Clostridium difficile</i> ," <i>Antimicrob. Agents Chemother.</i> 44:2254-2258 (2000).				
		National Committee for Clinical Laboratory Standards, Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria, Approved Standard M11-A5, 5 <sup>th</sup> ed. (2001).				
		Olson et al., Ten years of Prospective <i>Clostridium difficile</i> Associated Disease Surveillance and Treatment at the Minneapolis VA Medical Center 1982-1991," <i>Infect. Control Hosp. Epidemiol.</i> 15:371-381 (1994).				
		Peterson et al., "Antimicrobial Agents in <i>Clostridium Difficile</i> -Associated Intestinal Disease," <i>Antimicrob. Agents</i> 115-127 (1991).				
		Pothoulakis, C., "Pathogenesis of <i>Clostridium difficile</i> Associated Diarrhoea," <i>Eur. J. Gastroenterol. Hepatol.</i> 8:1041-1047, (1996).				
		Pothouakis et al., "CP-96, 345, a Substance P Antagonist, Inhibits Rat Intestinal Responses to <i>Clostridium difficile</i> Toxin A But Not Cholera Toxin," <i>Proc. Natl. Acad. Sci.</i> 91:947-951 (1994).				
		Pothoulakis et al., "Microbes and Microbial Toxins: Paradigms for Microbial-Mucosal Interactions II. The Integrated Response of the Intestine to <i>Clostridium difficile</i> Toxins," <i>Am. J. Physiol. Gastrointest. Liver Physiol.</i> 280:178-183 (2001).				
		"Recommendations for Preventing the Spread of Vancomycin Resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC)," <i>Am. J. Infect. Control</i> 23:87-94 (1995).				
		Sambol et al., "Infection of Hamsters with Epidemiologically Important Strains of <i>Clostridium difficile</i> ," <i>J. Infect. Dis.</i> 183:1760-1766 (2001).				
		Samore, "Epidemiology of Nosocomial <i>Clostridium difficile</i> Diarrhoea," <i>J. Hosp. Infect.</i> 43:S183-S190 (1999).				
		Teasley et al., "Prospective Randomised Trial of Metronidazole Versus Vancocymcin for <i>Clostridium-difficile</i> -associated Diarrhoea and Colitis," <i>Lancet</i> 2:1043-1046 (1983).				
		Tedesco et al., "Approach to Patients with Multiple Relapses of Antibiotic-Associated Pseudomembranous Colitis," <i>Am. J. Gastroenterol.</i> 80:867-868 (1985).				
		Wilcox et al., "Recurrence of Symptoms in <i>Clostridium difficile</i> Infection--Relapse or Reinfection?" <i>J. Hosp. Infect.</i> 38:93-100 (1998).				
BF		Zimmerman et al., "Review Article: Treatment of <i>Clostridium difficile</i> Infection," <i>Aliment. Pharmacol. Ther.</i> 11:1003-1012 (1997).				
EXAMINER		Blessing Fabiana		DATE CONSIDERED		4-01-05
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						